Affimed N.V. (AFMD) Releases Earnings Results, Beats Estimates By $0.03 EPS
Affimed N.V. (NASDAQ:AFMD) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03, Briefing.com reports. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The company had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.78 million. During the same period last year, the business earned ($0.31) EPS. Affimed N.V.’s quarterly revenue was down 44.4% compared to the same quarter last year.
Shares of Affimed N.V. (NASDAQ AFMD) traded down $0.05 on Tuesday, hitting $2.18. The stock had a trading volume of 104,274 shares, compared to its average volume of 299,730. The company has a quick ratio of 6.65, a current ratio of 6.69 and a debt-to-equity ratio of 0.13. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $2.95.
Several brokerages have weighed in on AFMD. SunTrust Banks, Inc. started coverage on Affimed N.V. in a research note on Thursday, July 13th. They set a “buy” rating and a $7.00 price objective on the stock. Jefferies Group LLC reaffirmed a “hold” rating and set a $2.50 target price on shares of Affimed N.V. in a research report on Thursday, July 27th. Finally, ValuEngine lowered Affimed N.V. from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Stock Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related stocks with our FREE daily email newsletter.